This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
BrainsWay continues to monitor the evolving impact of COVID-19 pandemic closely. Without question, our top priority is the health and wellbeing of our loyal and growing customer base, the patients they serve, and our employees and their families.
BrainsWay is doing our part to minimize the spread of COVID-19, such as:
We fully understand the importance of patients continuing to receive their Deep TMS treatment, and thus BrainsWay remains fully operational and committed to serving our customers to the best of our abilities.
We also know the role our industry plays is more essential than ever. And we know you are at the forefront of the battle against mental illness, providing crucial treatments to many patients who are struggling with severe depression and OCD. We would like to express our appreciation and admiration for all that you do for your patients.
We at BrainsWay are proud to be deeply engaged with many of you in providing the tools, support, and services, and most importantly, hope, to the many who depend on you in their daily lives. Thank you for your ongoing efforts.